Dilatam SR is a medicine applied across domains where additional symptomatic support is needed for several cardiovascular conditions. It is considered relevant to help manage symptoms in key areas related to heart and blood vessel health.

It is applied across therapeutic domains for easing discomfort associated with certain distressing symptoms, assisting in the management of conditions marked by increased physiological stress, and providing support for certain recurrent or episodic manifestations. The support offered helps patients cope more steadily. One patient-oriented benefit is captured simply as: “supports the patient during difficult episodes by easing distress.”

---

Easing Symptomatic Discomfort

Dilatam SR is commonly used in situations involving symptoms related to physical discomfort. It helps address symptom clusters that may become intense or disruptive, and provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. This medication assists with maintaining functional stability during phases of increased distress or discomfort.

Quick Fact: Applied for Symptoms that Interfere with Daily Functioning (Dilatam SR helps address symptoms that create noticeable physiological strain and may interfere with routine activities.)

Regulatory References

1. NIH MedlinePlus overview

Eligibility scope

The eligibility profile for Dilatam SR (diltiazem extended-release) is strictly defined by regulatory documents, which establish formal contraindications and require caution in specific patient populations.

---

Populations for whom use is contraindicated:

Contraindication Domain	Official Restriction
Cardiac Conduction	Sick sinus syndrome or second- or third-degree AV block, unless a functioning ventricular pacemaker is present.
Hemodynamic Stability	Severe hypotension (typically defined as systolic blood pressure less than 90 mm Hg).
Acute Event Status	Acute myocardial infarction accompanied by pulmonary congestion.
Hypersensitivity	Documented hypersensitivity to diltiazem hydrochloride or any of its components.

---

Eligibility-Related Restrictions and Caution:

• Impaired Organ Function: Use requires caution in patients with impaired renal or hepatic function. Monitoring of laboratory parameters is advised in these cases.
• Ventricular Function: Caution is required in patients with impaired ventricular function (e.g., heart failure), as worsening of heart failure has been reported.
• Age: The pediatric population (children) is generally excluded, as safety and efficacy have not been established. While older adults can use the medicine, caution and careful consideration of age-related declines in organ function are officially noted.
• Pregnancy/Lactation: Use during pregnancy is generally recommended only if the potential benefit justifies the potential risk. The drug passes into breast milk, which is a factor to consider for the infant.

This regulatory structure defines who must not use the medicine due to the risk of exacerbating severe pre-existing heart conditions and guides cautious use in vulnerable populations.

Dilatam SR (diltiazem) can interact with numerous prescription and non-prescription medicines, supplements, and certain foods, which may change how the medication works or increase the risk of side effects. It is essential to inform your healthcare provider about all products you are taking.

Potential Drug-Drug Interactions

Dilatam SR can significantly increase the blood levels of other drugs, potentially leading to increased toxicity. This is particularly relevant for the following classes of medicines:

Drug Class	Examples of Interacting Medicines	Potential Effect
Statins	Simvastatin, Lovastatin, Atorvastatin	Increased risk of muscle pain and damage (myopathy/rhabdomyolysis)
Immunosuppressants	Cyclosporine, Tacrolimus	Increased risk of kidney or liver problems
Cardiac Glycosides	Digoxin	Increased risk of digoxin toxicity (e.g., severe nausea, heart rhythm issues)

Combining Dilatam SR with other medications that slow the heart rate or lower blood pressure may lead to excessive effects, suchasing an unusually slow heart rate (bradycardia), very low blood pressure (hypotension), or heart block. These include:

• Beta-blockers (e.g., Metoprolol, Propranolol)
• Other calcium channel blockers
• Other blood pressure medicines (antihypertensives)
• Certain antiarrhythmics (e.g., Amiodarone, Quinidine)

The effectiveness of Dilatam SR may be reduced when taken with certain medications that increase the drug's metabolism, such as Rifampin (an antibiotic) and Phenytoin (an anti-seizure drug).

Food and Herbal Interactions

• Grapefruit Juice: Consuming grapefruit or grapefruit juice may significantly increase Dilatam SR levels in the blood, potentially increasing side effects. It is generally advised to avoid or limit consumption.
• Alcohol: Alcohol may enhance the blood pressure-lowering effects of Dilatam SR, leading to increased dizziness or fainting. It can also increase the absorption rate of the extended-release formulation, which may increase adverse effects. Limit or avoid alcohol intake.
• St. John's Wort: This herbal supplement may decrease the concentration of Dilatam SR in the blood, making it less effective. This combination should be avoided.

How Dilatam SR Works

The mechanism of action for Dilatam SR involves specific intervention at the molecular level, centered entirely on the L-type Voltage-Gated Calcium Channel ( Cav 1.2). By functioning as a slow-channel blocker, the drug impedes the entry of extracellular calcium ions ( Ca^2+) into cardiac and vascular smooth muscle cells, directly shaping the activity of three major physiological systems.

---

Modulating the Heart’s Electrical and Contractile Force

Diltiazem exhibits a negative chronotropic and dromotropic effect by blocking Ca^2+ influx into the pacemaker and conduction tissues of the Sinoatrial (SA) and Atrioventricular (AV) nodes. Simultaneously, the reduced Ca^2+ availability in the myocardium leads to a negative inotropic effect, which decreases the force of contraction.

---

Regulating Arterial Tone and Systemic Resistance

The same L-type channel blockade occurs in the vascular smooth muscle surrounding arteries, promoting muscle relaxation. This mechanism results in vasodilation by reducing the activation of the cellular machinery responsible for muscle contraction. The resulting physiological effect is a decrease in resistance to blood flow throughout the circulatory system.

---

Physiological Consequences of Dual Action

The drug's dual action—slowing the heart's electrical rhythm and inducing peripheral vasodilation—leads to a coordinated physiological outcome. The combination of reduced heart rate, decreased contractile force, and lowered systemic resistance collectively influences the overall metabolic and oxygen demand placed on the heart muscle.

How to Use Dilatam SR: Official Administration Principles

Dilatam SR (diltiazem hydrochloride extended-release) is administered based on official instructions that emphasize the preservation of its sustained-release (SR) mechanism. The only approved route of administration for this dosage form is oral, with the required frequency being once daily.

Standard Dosage and Use Parameters

The treatment course is chronic, and regulatory documents specify precise dosing limits and procedural constraints to ensure proper use.

Usage Parameter	Official Regulatory Guideline
Starting Dose (Adult)	Typically 120 mg to 240 mg once daily.
Maximum Daily Dose	Officially set at 540 mg once daily for certain extended-release formulations.
Dose Titration Schedule	Dose adjustments should occur at intervals of 7 to 14 days to allow the full stable effect to be established.

Administration Requirements

To maintain the prolonged absorption profile, the capsules or tablets must be swallowed whole and should not be crushed, split, or chewed. The medication can generally be taken without regard to food for many formulations. For populations such as older adults or those with impaired hepatic/renal function, a lower starting dose is advised, and dose increases must be conducted slowly with careful monitoring. The use of Dilatam SR is not established in the pediatric population.

Research Evidence / Overview of Studies for Dilatam SR

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research has primarily used Randomized Controlled Trials (RCTs) to examine how Dilatam SR is associated with changes in blood pressure levels. These trials were designed to compare the medicine against both an inactive substance (placebo) and other common medications used in this context. The key outcomes measured in these studies included the change in blood pressure throughout the day and the long-term patterns related to the occurrence of major cardiovascular events like strokes or heart attacks.

Studies have reported consistent measurements demonstrating a change in blood pressure levels when compared to the inactive control groups. Long-term studies, which observed patients for several years, also described patterns of cardiovascular event occurrences that were monitored when the agent was compared against other types of blood pressure medications. This evidence contributes to the broader evidence landscape regarding blood pressure over extended periods.

Evidence for Use in Addressing Chronic Stable Angina

The research exploring the use of Dilatam SR in contexts involving symptoms of chronic stable angina (chest discomfort) often uses controlled study designs. Researchers monitored outcomes related to physical discomfort, primarily focusing on functional capacity, measured by the time patients could continue a standardized exercise test. Trials reported that participants assigned to the medicine's group reported measurements of extended exercise time compared to the placebo groups, and trials monitored changes in the reported number of weekly anginal episodes.

A key limitation is that these studies mostly focused on short-term outcomes like exercise time and reported symptom counts. Limited long-term outcome data directly linking these short-term findings to a reduced risk of major cardiovascular events in the angina-only population, meaning the long-term effects are not fully established for this specific clinical context.

Evidence for Heart Rate Control in Atrial Arrhythmias

The use of diltiazem for contexts involving a rapid ventricular rate in conditions like atrial fibrillation or atrial flutter is based on its known characteristics related to the heart’s electrical system. The evidence is derived from both RCTs (often using non-SR forms) and observational studies that have tracked chronic heart rate management. These studies monitored the measures related to heart rate, reporting how heart rate changed in the observed populations.

Research Gaps and Areas of Uncertainty

The follow-up durations in clinical trials varied significantly depending on the indication studied. While evidence exists from long-term follow-up for high blood pressure, research is still limited regarding long-term outcomes for other conditions. Data for certain groups remain insufficient, including children or patients with significant impairment of the heart's pumping function. The results apply mainly to the populations studied in the key clinical trials, and the level of certainty varies for conditions or patient groups where comprehensive research is still emerging.

Key Studies & References

1. Diltiazem Hydrochloride Extended-release Capsules, USP - FDA/DailyMed Package Insert
2. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina
3. Emergency Department Management of Recent-Onset Atrial Fibrillation with Rapid Ventricular Response (AFib Rate Control Guidelines)

Common questions about Dilatam SR (FAQ)

Q: What's the difference between Dilatam and Dilatam SR?

The SR in Dilatam SR stands for Sustained-Release. According to official regulatory documents, this formulation is engineered to release the active ingredient slowly and steadily over many hours.

This sustained-release mechanism is designed to provide a prolonged period of therapeutic effect throughout the day compared to immediate-release versions of the medicine.

Q: Do you have to take Dilatam SR at the exact same time every day?

Official regulatory texts specify that Dilatam SR is administered once daily. Consistent daily timing is generally recommended by healthcare professionals to help maintain stable therapeutic levels in the bloodstream.

Maintaining a stable concentration helps ensure the drug works as intended throughout the 24-hour period.

Q: Are there any specific vitamins or supplements that shouldn't be taken with Dilatam SR?

Regulatory documents list the herbal product St. John's Wort as a potential interaction, noting that it may decrease the medicine's levels and should therefore be avoided.

Specific vitamins or common mineral supplements are typically not listed, but official product information advises informing a healthcare professional about all products being taken.

Q: What is the risk of having a serious side effect from Dilatam SR?

Regulatory authorities classify adverse events by their reported frequency in clinical studies and post-marketing surveillance. Serious reactions such as severe heart block, heart failure, or severe skin reactions are typically listed in the rare or very rare frequency categories in official documentation.

Q: Why is Dilatam SR used for two different conditions (like high blood pressure and angina)?

Official descriptions explain that the drug works by affecting both the heart's electrical system (reducing rate and force) and the blood vessels (causing them to relax).

This combined action addresses conditions related to circulatory resistance (high blood pressure) and conditions where the heart's workload needs to be reduced (angina).

Q: Can Dilatam SR affect my ability to drive or operate machinery?

Official regulatory texts commonly state that the medicine may cause effects such as dizziness or fatigue, which could potentially impair the ability to drive or operate complex machinery.

Official information notes that these effects are particularly important to consider when treatment is initiated or following a dose adjustment.

Q: What should I do if I notice swelling in my ankles while taking Dilatam SR?

Peripheral edema (swelling in the ankles or feet) is officially listed as a common side effect of Dilatam SR.

If this or any other side effect is noticed, particularly if it is persistent or concerning, it is important to communicate this information to a healthcare professional for assessment.

Q: What kind of monitoring (e.g., blood tests) is usually recommended while on Dilatam SR?

Regulatory documents recommend careful monitoring for patients with pre-existing impaired renal or hepatic function.

Additionally, monitoring of drug levels or organ function may be required when Dilatam SR is used with certain interacting medicines, such as Digoxin or Statins, as described in official interaction sections.

Q: Can taking Dilatam SR affect future pregnancy or fertility?

Official regulatory texts advise that the drug should generally be used during pregnancy only if the potential benefit justifies the potential risk. The medicine is also known to pass into breast milk.

Information regarding effects on human fertility (the ability to conceive) is often noted in regulatory documentation as having no clinical data or not being established.

Q: What is the long-term safety profile of Dilatam SR?

The safety profile is derived from adverse effects reported in clinical trials and post-marketing surveillance collected over time.

Studies show the medicine's side effect profile is generally consistent in the populations studied over the duration of the clinical research.

Q: What are the signs of an allergic reaction to Dilatam SR?

Regulatory documents instruct patients to seek immediate medical attention if signs of a hypersensitivity reaction occur. These signs may include a rash, itching, swelling of the face, tongue, or throat, or trouble breathing.

Official warnings related to hypersensitivity reactions are provided in the product information.

Q: Can Dilatam SR interact with cold or flu medicines?

Regulatory warnings on interactions caution against combining Dilatam SR with other medicines that may significantly raise blood pressure. This may include certain active ingredients found in over-the-counter cold and flu medicines, such as decongestants.

These interacting ingredients can counteract the blood pressure-lowering action of Dilatam SR.

Q: Does Dilatam SR affect kidney function over time?

Regulatory guidance notes that caution and monitoring are required in patients with pre-existing renal impairment because the drug is cleared by the kidneys.

There are no official statements that the drug causes damage to normal kidney function over time.

Q: How long does it typically take for Dilatam SR to start working?

Official regulatory documents describe the period needed to reach the highest concentration of the drug in the bloodstream, known as the time to peak plasma concentration.

For sustained-release formulations like Dilatam SR, this period is typically several hours after administration.

Q: Can Dilatam SR cause weight gain?

Official adverse event lists for the active ingredient sometimes include weight gain or edema (swelling) as an uncommon or rare reported event.

Edema, which is listed as common, can sometimes be perceived as weight gain by patients.

Q: Does Dilatam SR interact with common painkillers like ibuprofen?

Regulatory documents generally warn against concurrent use with drugs that may counteract the desired effects of Dilatam SR. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), such as ibuprofen, are officially recognized as having the potential to diminish the blood pressure-lowering effect of antihypertensive medicines.

Q: Can Dilatam SR affect blood sugar levels?

Official adverse event lists for the active ingredient sometimes include changes in blood glucose levels.

Elevated blood sugar, known as hyperglycemia, is typically classified as an uncommon or rare side effect reported in regulatory documents.

Q: Can I stop taking Dilatam SR suddenly if I feel better?

Official regulatory texts often contain warnings that abrupt discontinuation of certain cardiovascular medicines should be avoided. Discontinuing the medicine suddenly may be associated with the risk of increased frequency or severity of certain cardiac events.

Changes to treatment should only be made following consultation with a healthcare professional.

Q: What happens if I miss a dose of Dilatam SR?

Official guidance documents provide specific instructions regarding the management of a missed dose.

These instructions typically specify when it may be appropriate to take the missed dose and caution against taking more than the prescribed amount.

Q: Does Dilatam SR cause hair loss?

Official adverse event lists for the active ingredient sometimes include dermatological events like alopecia (hair loss).

This effect is typically classified as a very rare or post-marketing report event in regulatory documents.

Q: Is it normal to have vivid dreams on Dilatam SR?

Regulatory adverse event lists for the active ingredient sometimes include nervous system effects such as insomnia or nervousness.

Changes in sleep quality or dreams are rarely noted, often classified as rare side effects.

Q: Is Dilatam SR habit-forming or addictive?

Regulatory texts typically include a section on Dependence or Abuse Potential for prescription medicines.

For this drug class, official documents usually state that the medicine has no recognized potential for dependence or abuse.

Q: Can I take Dilatam SR if I have asthma?

Regulatory documents include guidance for use in patients with certain respiratory conditions.

The prescribing information includes guidance for use in patients with conditions like asthma or other pulmonary issues, which requires careful assessment by a healthcare professional.

Q: Is there a link between Dilatam SR and changes in mood?

Official adverse event lists for the active ingredient sometimes include psychiatric side effects such as depression or nervousness.

These effects are typically classified as uncommon or rare events reported during clinical trials or post-marketing surveillance.

Q: What should I do if my side effects don't go away after a few weeks on Dilatam SR?

Official patient information consistently states that if side effects are experienced or persist, communication with a healthcare professional is necessary.

This enables a healthcare professional to assess the effect and determine appropriate monitoring or management steps.

How to Store and Dispose of Dilatam SR?

The storage and disposal of Diltiazem hydrochloride extended-release capsules (Dilatam SR) must strictly adhere to official regulatory requirements to maintain product stability and ensure public safety.

Storage Requirements

Condition	Requirement
Temperature	Store at 25 C (77 F), with excursions permitted between 15 C and 30 C.
Protection	Avoid excessive humidity and protect from light.
Packaging	Keep in a tight, light-resistant container with a child-resistant closure.
Child Safety	Keep out of reach of children.

Disposal Requirements

Unused or expired medication must be disposed of according to local, regional, and national regulations. To protect the environment, the product should generally not be flushed down a drain or thrown into household trash unless official guidance explicitly permits it.